Drugs / MTL-CEBPA
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT05097911 | Aug 2021 → Apr 2026 overdue | hepatocellular carcinoma | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04105335 | Nov 2019 → Jan 2025 | cancer | Mina Alpha Limited | Completed | No outcome recorded |
| Phase 1 | NCT02716012 | Mar 2016 → Jul 2025 | hepatocellular carcinoma | Mina Alpha Limited | Unknown | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT04710641 | Jan 2022 → Jan 2025 | hepatitis B virus infection, hepatitis C virus infection, hepatocellular carcinoma | Mina Alpha Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2023-10-25 | Mina Alpha Limited | Results MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting minatx.com ↗
Findings demonstrate structure-activity relationship of RNAa therapeutics, supporting use in genetic medicine, as well as therapeutic potential of MiNA’s MTL-CEBPA in acute myeloid leukemia |
| 2023-04-14 | Mina Alpha Limited | Results MiNA Therapeutics Presents Late-Breaking Positive Phase 1b Data for MTL-CEBPA in Combination with an Anti-PD1 Checkpoint Inhibitor at the Annual American Association of Cancer Research (AACR) Meeting minatx.com ↗
Findings from the Phase 1b portion of the study validate the clinical proof of mechanism of MTL-CEBPA as a combination treatment and identify a novel predictive biomarker of clinical response. |
| 2022-11-11 | Mina Alpha Limited | Results MiNA Therapeutics presents positive Phase 1b data on MTL-CEBPA in combination with anti-PD1 checkpoint inhibitor minatx.com ↗
MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA (RNAa) therapeutics, presents positive data from its Phase 1a/b TIMEPOINT study of MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours. |
| 2021-11-12 | Mina Alpha Limited | Results MiNA Therapeutics highlights clinical data supporting the further development of MTL-CEBPA as an anti-cancer immunotherapy minatx.com ↗
Positive Phase 1a data presented at SITC demonstrates safety, tolerability and clinical activity of MTL-CEBPA in combination with pembrolizumab, supporting continued development in solid tumour malignancies |
| 2021-04-09 | Mina Alpha Limited | Results MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment minatx.com ↗
In pre-clinical studies, MTL-CEBPA was shown to counteract a key cancer immune evasion pathway by inhibiting immune suppression by myeloid cells. |
| 2020-05-29 | Mina Alpha Limited | Results MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL CEBPA in Combination with Sorafenib in Liver Cancer at 2020 ASCO Annual Meeting minatx.com ↗
The study met its primary e ndpoints of safety and tolerability for MTL-CEBPA administered either concomitantly or sequentially with sorafenib. |
| 2020-05-27 | Mina Alpha Limited | Results MiNA Therapeutics Announces Publication of Phase I Liver Cancer Data in Clinical Cancer Research and Provides Update on Clinical Development and Drug Discovery Programs minatx.com ↗
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the publication of data from its Phase I liver cancer trial, OUTREACH, in Clinical Cancer Research. |
| 2019-09-30 | Mina Alpha Limited | Results MiNA Therapeutics Presents Clinical and Pre-Clinical Data at ESMO Supporting MTL-CEBPA as Immunological Combination Treatment minatx.com ↗
--Final results from Phase 1 study of MTL-CEBPA in advanced liver cancer patients demonstrate clinical activity and attractive safety profile-- |
| 2019-04-02 | Mina Alpha Limited | Results MiNA Therapeutics Presents Pre-Clinical Data Supporting Combination of MTL-CEBPA with Sorafenib and Other Cancer Treatments at AACR minatx.com ↗
MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced pre-clinical data supporting the immunological effects of MTL-CEBPA and its benefits in combination with other anti-cancer interventions including sorafenib, anti-PD1 checkpoint inhibition and radiofrequency ablation. |
| 2018-09-19 | Mina Alpha Limited | Results MiNA Therapeutics Announces Findings From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference minatx.com ↗ |
| 2018-06-04 | Mina Alpha Limited | Results MiNA Therapeutics Presents Initial Results from First-in-Human MTL-CEBPA Study in Advanced Liver Cancer Patients minatx.com ↗
In the study, MTL-CEBPA was generally well tolerated in patients with both healthy and impaired liver function and provided evidence of anti-tumour activity. |
| 2018-03-09 | Mina Alpha Limited | Results MiNA Therapeutics Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease minatx.com ↗
“The combination of beneficial effects observed across a range of liver disease models supports a unique and promising role for MTL-CEBPA therapy in the treatment of liver diseases and liver cancer,” commented Robert Habib, CEO of MiNA Therapeutics. |
| 2017-09-06 | Mina Alpha Limited | Results MiNA Therapeutics Announces Publication of Pre-Clinical Data Supporting On-Target Mechanism of Action of Clinical Candidate MTL-CEBPA minatx.com ↗
A number of scientific findings of CEBPA-51 were reported including a direct gene activation mechanism evidenced by physical interaction of CEBPA-51 at the CEBPA gene and increased transcriptional activity of the CEBPA gene. |
All press releases naming this drug 18 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTL-CEBPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05097911 ↗ |
| Action | Activate | “upregulates C/EBP-α” PMID 32357963 ↗ May 2020 |
| Modality | Small activating RNA (saRNA) | “small activating RNA oligonucleotide drug” PMID 32357963 ↗ May 2020 |
| Route | Intravenous | “Intravenous administration” NCT02716012 ↗ |
| Target | CEBPA | “MTL-CEBPA is administered as monotherapy or in combination with sorafenib to patients with advanced hepatocellular carcinoma and cirrhosis of the liver. All participants will...” NCT02716012 ↗ |